SLNO
HEALTHCARESoleno Therapeutics Inc
AI Insight
What's Moving SLNO Today?
No stock-specific AI insight has been generated for SLNO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$29.43$90.32
$52.94
Fundamentals
Market Cap$2.8B
P/E Ratio27.5
EPS$1.93
Dividend Yield—
Dividend / Share—
ROE26.4%
Profit Margin33.7%
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding52.1M
SLNO News
65 articles- Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal PeriodThe Missoulian·Jun 16, 2026
- NBIX: Multi-product growth, major acquisition, and robust pipeline drive strong financial and patient impactTradingView·Jun 2, 2026
- Neurocrine Biosciences Completes Acquisition of Soleno TherapeuticsYahoo Finance·May 18, 2026
- Soleno Merger With Neurocrine Puts Profitability And Valuation In FocusYahoo Finance·May 11, 2026
- Neurocrine Biosciences Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Neurocrine Biosciences Reports First-Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition DealYahoo Finance·May 1, 2026
- SOLENO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNOGlobeNewswire Inc.·Apr 29, 2026
- Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc.·Apr 28, 2026
- Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff DeadlineGlobeNewswire Inc.·Apr 27, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 27, 2026
- SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Hyperphagia Drug Launch Disruptions – Hagens BermanGlobeNewswire Inc.·Apr 24, 2026
- SLNO 13-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions – Hagens BermanGlobeNewswire Inc.·Apr 22, 2026
- Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Apr 22, 2026
- ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 21, 2026
- ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SLNOGlobeNewswire Inc.·Apr 21, 2026
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOMGlobeNewswire Inc.·Apr 21, 2026
- Deadline Alert: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc.·Apr 20, 2026
- CORT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORTGlobeNewswire Inc.·Apr 18, 2026
- ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNOGlobeNewswire Inc.·Apr 18, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 16, 2026
- DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsGlobeNewswire Inc.·Apr 16, 2026
- Halper Sadeh LLC is Investigating Whether MKC, OMEX, SLNO, FORA are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc.·Apr 15, 2026
- Halper Sadeh LLC is Investigating Whether AVNS, LEG, SLNO, FORA are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc.·Apr 15, 2026
- Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome CaregiversYahoo Finance·Apr 15, 2026
- ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Super Micro Computer, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SMCIGlobeNewswire Inc.·Apr 10, 2026
- Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's WhyYahoo Finance·Apr 8, 2026
- Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation StoryYahoo Finance·Apr 7, 2026
- Arm downgraded, Arista Networks upgraded: Wall Street's top analyst callsYahoo Finance·Apr 7, 2026
- Company News for Apr 7, 2026Yahoo Finance·Apr 7, 2026
- Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion MergerYahoo Finance·Apr 7, 2026
- Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout AgreementMotley Fool·Apr 6, 2026
- Why Soleno Therapeutics Stock Rocketed Higher on MondayMotley Fool·Apr 6, 2026
- Nasdaq, S&P 500 Notch 4th Consecutive Gain Amid Uncertainty Around Iran War CeasefireYahoo Finance·Apr 6, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Apr 6, 2026
- Neurocrine Agrees $2.9 Billion Soleno Deal At 34% PremiumYahoo Finance·Apr 6, 2026
- Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play.Yahoo Finance·Apr 6, 2026
- Equities Mostly Rise Intraday, Oil Advances as Markets Monitor Ceasefire ProspectsYahoo Finance·Apr 6, 2026
- Sector Update: Health Care Stocks Softer Monday AfternoonYahoo Finance·Apr 6, 2026
- Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a ShareMarketbeat·Apr 6, 2026
Price Data
Open$0.00
Previous Close$52.92
Day High$0.00
Day Low$0.00
52 Week High$90.32
52 Week Low$29.43
52-Week Range
$29.43$90.32
$52.94
Fundamentals
Market Cap$2.8B
P/E Ratio27.5
EPS$1.93
Dividend Yield—
Dividend / Share—
ROE26.4%
Profit Margin33.7%
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding52.1M
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—